文献速递瓣膜外科

低风险患者经导管主动脉瓣植入与外科手术的院内及中期结局比较

Transcatheter aortic valve implantation versus surgery in low-risk patients: in-hospital and mid-term outcomes.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-01-01

结果显示TAVI组中期全因死亡率更高(HR 0.38,95%CI 0.23-0.88,P=0.020),且术后传导异常和瓣周漏发生率更高,而AVR组术后急性肾损伤发生率更高。匹配队列中结果一致。

要点

  • 低风险患者TAVI中期全因死亡率高于AVR(HR 0.38,95%CI 0.23-0.88)。
  • TAVI术后左束支传导阻滞和至少轻中度瓣周漏发生率更高。
  • AVR术后急性肾损伤发生率更高,TAVI组永久起搏器植入率在匹配队列中更高。

核心结论

  • 低风险重度主动脉瓣狭窄患者中,TAVI组中期全因死亡率高于AVR组,且术后传导异常和瓣周漏发生率更高,仍需关注。

主要发现

  • TAVI组患者年龄更大(82[78-83] vs 78[77-80],P<0.001),晚期慢性肾病(33.3% vs 15.7%,P<0.001)、活动能力差(15.6% vs 5.6%,P=0.008)比例及EuroSCORE II(2.2[1.72-2.98] vs 1.9[1.31-2.46],P=0.002)更高。
  • AVR组术后急性肾损伤发生率更高(29.6% vs 4.5%,P<0.001),TAVI组左束支传导阻滞(23.9% vs 1.8%,P<0.001)和至少轻中度瓣周漏(4.5% vs 0%,P=0.021)发生率更高。
  • 中期全因死亡率TAVI组更高(HR 0.38,95%CI 0.23-0.88,P=0.020);匹配队列中TAVI组左束支传导阻滞(11.5% vs 1.3%,P=0.018)和永久起搏器植入(12.8% vs 5.1%,P=0.041)发生率更高,AVR组急性肾损伤更高(33.3% vs 5.1%,P<0.001),中期死亡率TAVI组仍更高(HR 0.36,95%CI 0.21-0.87,P=0.019)。

临床怎么用

  • 在低外科风险75至85岁重度主动脉瓣狭窄患者中,选择TAVI需权衡其中期死亡风险及传导异常、瓣周漏风险,AVR需注意急性肾损伤风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of our study is to compare post-procedural outcomes and mid-term mortality of low-risk patients treated by transfemoral TAVI or surgical aortic valve replacement (AVR) for severe aortic stenosis. METHODS: Data of consecutive patients undergoing AVR or TAVI from September 2017 to December 2021 were prospectively collected and retrospectively reviewed. Eligible patients were aged between 75 and 85 years with low-surgical risk and isolated severe aortic stenosis. Exclusion criteria were prior heart surgery, valve-in-valve procedure and the need for concomitant procedures. The primary end-point was mid-term all-cause mortality. RESULTS: Three hundred fifty-one patients were enrolled. Of these, 243 underwent TAVI and 108 underwent AVR. Compared to AVR, TAVI patients were older (82 [78-83 ] vs 78 [77-80], P < 0.001), with higher incidence of advanced chronic kidney disease (33.3% vs 15.7%, P < 0.001) and poor mobility (15.6% vs 5.6%, P = 0.008) and a higher Euroscore II (2.2 [1.72-2.98] vs 1.9 [1.31-2.46 ], P = 0.002). AVR patients had a higher incidence of post-procedural AKI (29.6% vs 4.5%, P < 0.001), while TAVI patients had a higher incidence of LBBB (23.9% vs 1.8%, P < 0.001) and at least mild to moderate PVL (4.5% vs 0%, P = 0.021). Mid-term mortality was higher among TAVI patients (HR 0.38 [95% CI 0.23-0.88], P = 0.020). In the matched cohort, TAVI had a higher incidence of LBBB (11.5% vs 1.3%, P = 0.018) and permanent PM implantation (12.8% vs 5.1%, P = 0.041), while AVR patients had a higher incidence of post-procedural AKI (33.3% vs 5.1%, P < 0.001). Mid-term mortality was higher in TAVI patients (HR 0.36 [95% CI 0.21-0.87], P = 0.019). CONCLUSIONS: TAVI patients demonstrated a higher mid-term mortality and a higher incidence of post-procedural conduction abnormalities and PVL which remain a concern in low-risk patients.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Lodo V, Italiano EG, Weltert L, et al. Transcatheter aortic valve implantation versus surgery in low-risk patients: in-hospital and mid-term outcomes. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 40293726. doi:10.1093/icvts/ivaf103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。